Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A

Given that we have been away for a couple of weeks, this Bulletin is chock-full of news and analysis of recent events… This Week: Beckley Psytech Acquires Eleusis – Our Quick Analysis Empyrean Neuroscience Scoops $22m Series A to Genetically Engineer Small Molecule Therapeutics from Fungi and Plants DEA Increases Production Quotas for Psychedelics, Again Deep Dive: COMPASS Pathways Reveals Phase 3…

Source